@article{ZwinkJenetzkySchmiedekeetal.2012,
  author    = {Zwink, Nadine and Jenetzky, Ekkehart and Schmiedeke, Eberhard and Schmidt, Dominik and M{\"a}rzheuser, Schmidt and Grasshoff-Derr, Sabine and Holland-Cunz, Stefan and Weih, Sandra and Hosie, Stuart and Reifferscheid, Peter and Ameis, Helen and Kujath, Christina and Rissmann, Anke and Obermayr, Florian and Schwarzer, Nicole and Bartels, Enrika and Reutter, Heiko and Brenner, Hermann},
  title     = {Assisted reproductive techniques and the risk of anorectal malformations: a German case-control study},
  series = {Orphanet Journal of Rare Diseases},
  volume    = {7},
  journal   = {Orphanet Journal of Rare Diseases},
  number    = {65},
  organization    = {CURE-Net Consortium},
  doi       = {10.1186/1750-1172-7-65},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134036},
  year      = {2012},
  abstract  = {Background: The use of assisted reproductive techniques (ART) for treatment of infertility is increasing rapidly worldwide. However, various health effects have been reported including a higher risk of congenital malformations. Therefore, we assessed the risk of anorectal malformations (ARM) after in-vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). Methods: Data of the German Network for Congenital Uro-REctal malformations (CURE-Net) were compared to nationwide data of the German IVF register and the Federal Statistical Office (DESTATIS). Odds ratios (95\% confidence intervals) were determined to quantify associations using multivariable logistic regression accounting for potential confounding or interaction by plurality of births. Results: In total, 295 ARM patients born between 1997 and 2011 in Germany, who were recruited through participating pediatric surgeries from all over Germany and the German self-help organisation SoMA, were included. Controls were all German live-births (n = 10,069,986) born between 1997 and 2010. Overall, 30 cases (10\%) and 129,982 controls (1\%) were born after IVF or ICSI, which translates to an odds ratio (95\% confidence interval) of 8.7 (5.9-12.6) between ART and ARM in bivariate analyses. Separate analyses showed a significantly increased risk for ARM after IVF (OR, 10.9; 95\% CI, 6.2-19.0; P < 0.0001) as well as after ICSI (OR, 7.5; 95\% CI, 4.6-12.2; P < 0.0001). Furthermore, separate analyses of patients with isolated ARM, ARM with associated anomalies and those with a VATER/VACTERL association showed strong associations with ART (ORs 4.9, 11.9 and 7.9, respectively). After stratification for plurality of birth, the corresponding odds ratios (95\% confidence intervals) were 7.7 (4.6-12.7) for singletons and 4.9 (2.4-10.1) for multiple births. Conclusions: There is a strongly increased risk for ARM among children born after ART. Elevations of risk were seen after both IVF and ICSI. Further, separate analyses of patients with isolated ARM, ARM with associated anomalies and those with a VATER/VACTERL association showed increased risks in each group. An increased risk of ARM was also seen among both singletons and multiple births.},
  language  = {en}
}
@article{ZaitsevaHoffmannOttoetal.2022,
  author    = {Zaitseva, Olena and Hoffmann, Annett and Otto, Christoph and Wajant, Harald},
  title     = {Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy},
  series = {Frontiers in Pharmacology},
  volume    = {13},
  journal   = {Frontiers in Pharmacology},
  issn      = {1663-9812},
  doi       = {10.3389/fphar.2022.935086},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-290238},
  year      = {2022},
  abstract  = {Fibroblast growth factor-inducible 14 (Fn14) is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and is activated by its ligand TNF-like weak inducer of apoptosis (TWEAK). The latter occurs as a homotrimeric molecule in a soluble and a membrane-bound form. Soluble TWEAK (sTWEAK) activates the weakly inflammatory alternative NF-κB pathway and sensitizes for TNF-induced cell death while membrane TWEAK (memTWEAK) triggers additionally robust activation of the classical NF-κB pathway and various MAP kinase cascades. Fn14 expression is limited in adult organisms but becomes strongly induced in non-hematopoietic cells by a variety of growth factors, cytokines and physical stressors (e.g., hypoxia, irradiation). Since all these Fn14-inducing factors are frequently also present in the tumor microenvironment, Fn14 is regularly found to be expressed by non-hematopoietic cells of the tumor microenvironment and most solid tumor cells. In general, there are three possibilities how the tumor-Fn14 linkage could be taken into consideration for tumor therapy. First, by exploitation of the cancer associated expression of Fn14 to direct cytotoxic activities (antibody-dependent cell-mediated cytotoxicity (ADCC), cytotoxic payloads, CAR T-cells) to the tumor, second by blockade of potential protumoral activities of the TWEAK/Fn14 system, and third, by stimulation of Fn14 which not only triggers proinflammtory activities but also sensitizes cells for apoptotic and necroptotic cell death. Based on a brief description of the biology of the TWEAK/Fn14 system and Fn14 signaling, we discuss the features of the most relevant Fn14-targeting biologicals and review the preclinical data obtained with these reagents. In particular, we address problems and limitations which became evident in the preclinical studies with Fn14-targeting biologicals and debate possibilities how they could be overcome.},
  language  = {en}
}
@article{ZaitsevaHoffmannLoestetal.2023,
  author    = {Zaitseva, Olena and Hoffmann, Annett and L{\"o}st, Margaretha and Anany, Mohamed A. and Zhang, Tengyu and Kucka, Kirstin and Wiegering, Armin and Otto, Christoph and Wajant, Harald},
  title     = {Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity},
  series = {Frontiers in Immunology},
  volume    = {14},
  journal   = {Frontiers in Immunology},
  doi       = {10.3389/fimmu.2023.1194610},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-323116},
  year      = {2023},
  abstract  = {Fibroblast growth factor (FGF)-inducible 14 (Fn14) activates the classical and alternative NFκB (nuclear factor 'kappa-light-chain-enhancer' of activated B-cells) signaling pathway but also enhances tumor necrosis factor (TNF)-induced cell death. Fn14 expression is upregulated in non-hematopoietic cells during tissue injury and is also often highly expressed in solid cancers. In view of the latter, there were and are considerable preclinical efforts to target Fn14 for tumor therapy, either by exploiting Fn14 as a target for antibodies with cytotoxic activity (e.g. antibody-dependent cellular cytotoxicity (ADCC)-inducing IgG variants, antibody drug conjugates) or by blocking antibodies with the aim to interfere with protumoral Fn14 activities. Noteworthy, there are yet no attempts to target Fn14 with agonistic Fc effector function silenced antibodies to unleash the proinflammatory and cell death-enhancing activities of this receptor for tumor therapy. This is certainly not at least due to the fact that anti-Fn14 antibodies only act as effective agonists when they are presented bound to Fcγ receptors (FcγR). Thus, there are so far no antibodies that robustly and selectively engage Fn14 signaling without triggering unwanted FcγR-mediated activities. In this study, we investigated a panel of variants of the anti-Fn14 antibody 18D1 of different valencies and domain architectures with respect to their inherent FcγR-independent ability to trigger Fn14-associated signaling pathways. In contrast to conventional 18D1, the majority of 18D1 antibody variants with four or more Fn14 binding sites displayed a strong ability to trigger the alternative NFκB pathway and to enhance TNF-induced cell death and therefore resemble in their activity soluble (TNF)-like weak inducer of apoptosis (TWEAK), one form of the natural occurring ligand of Fn14. Noteworthy, activation of the classical NFκB pathway, which naturally is predominately triggered by membrane-bound TWEAK but not soluble TWEAK, was preferentially observed with a subset of constructs containing Fn14 binding sites at opposing sites of the IgG scaffold, e.g. IgG1-scFv fusion proteins. A superior ability of IgG1-scFv fusion proteins to trigger classical NFκB signaling was also observed with the anti-Fn14 antibody PDL192 suggesting that we identified generic structures for Fn14 antibody variants mimicking soluble and membrane-bound TWEAK.},
  language  = {en}
}
@article{WollbornWunderStixetal.2015,
  author    = {Wollborn, Jakob and Wunder, Christian and Stix, Jana and Neuhaus, Winfried and Bruno, Rapahel R. and Baar, Wolfgang and Flemming, Sven and Roewer, Norbert and Schlegel, Nicolas and Schick, Martin A.},
  title     = {Phosphodiesterase-4 inhibition with rolipram attenuates hepatocellular injury in hyperinflammation in vivo and in vitro without influencing inflammation and HO-1 expression},
  series = {Journal of Pharmacology and Pharmacotherapeutics},
  volume    = {6},
  journal   = {Journal of Pharmacology and Pharmacotherapeutics},
  number    = {1},
  doi       = {10.4103/0976-500X.149138},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-149336},
  pages     = {13-23},
  year      = {2015},
  abstract  = {Objective: To investigate the impact of the phophodiesterase-4 inhibition (PD-4-I) with rolipram on hepatic integrity in lipopolysaccharide (LPS) induced hyperinflammation. Materials and Methods: Liver microcirculation in rats was obtained using intravital microscopy. Macrohemodynamic parameters, blood assays, and organs were harvested to determine organ function and injury. Hyperinflammation was induced by LPS and PD-4-I rolipram was administered intravenously one hour after LPS application. Cell viability of HepG2 cells was measured by EZ4U-kit based on the dye XTT. Experiments were carried out assessing the influence of different concentrations of tumor necrosis factor alpha (TNF-α) and LPS with or without PD-4-I. Results: Untreated LPS-induced rats showed significantly decreased liver microcirculation and increased hepatic cell death, whereas LPS + PD-4-I treatment could improve hepatic volumetric flow and cell death to control level whithout influencing the inflammatory impact. In HepG2 cells TNF-α and LPS significantly reduced cell viability. Coincubation with PD-4-I increased HepG2 viability to control levels. The heme oxygenase 1 (HO-1) pathway did not induce the protective effect of PD-4-I. Conclusion: Intravenous PD-4-I treatment was effective in improving hepatic microcirculation and hepatic integrity, while it had a direct protective effect on HepG2 viability during inflammation.},
  language  = {en}
}
@article{WinotoMorbachUlrichsLeyhausenetal.1989,
  author    = {Winoto-Morbach, Supandi and Ulrichs, Karin and Leyhausen, Gaby and M{\"u}ller-Ruchholtz, Wolfgang},
  title     = {New principle for large-scale preparation of purified human pancreas islets},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45600},
  year      = {1989},
  abstract  = {Because successful human islet transplantation requires large quantities of viable islets that must be separated from the highly immunogenic exocrine tissue and because handpicking is too time-consuming and laborious to be clinically relevant, a new approach for solving this problem has been established in rat models. It is based on the principle that magnetic microspheres (MMSs) coupled to lectins with binding specificity for the exocrine tissue portion are trapped in an electromagnetic field, thus providing effluent islets of a high degree of purity. In this study our aim was to adapt this princip'le to human islet preparations. In this context our prime interest was focused on a lectin suitable for human pancreatic tissue. Of 19 different lectins tested, only 1, Wisteria floribunda agglutinin (WFA), is suitable, as shown by immunofluorescence, MMS-Iectin binding, and magnetic separation},
  subject      = {Immunbiologie},
  language  = {en}
}
@inproceedings{WinotoMorbachUlrichsMuellerRuchholtz1991,
  author    = {Winoto-Morbach, S. and Ulrichs, Karin and M{\"u}ller-Ruchholtz, W.},
  title     = {New Developments in Biodegradable Microspheres For Magnetic Separation Techniques},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45712},
  year      = {1991},
  abstract  = {No abstract available},
  subject      = {Immunbiologie},
  language  = {en}
}
@article{WinotoMorbachUlrichsHeringetal.1990,
  author    = {Winoto-Morbach, S. and Ulrichs, Karin and Hering, BJ and Leyhausen, G. and M{\"u}ller-Ruchholtz, W.},
  title     = {Lectins for electromagnetic purification of islets from humans and large mammals},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45430},
  year      = {1990},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@article{WinotoMorbachLeyhausenSchuenkeetal.1989,
  author    = {Winoto-Morbach, S. and Leyhausen, G. and Sch{\"u}nke, M. and Ulrichs, Karin and M{\"u}ller-Buchholtz, W.},
  title     = {Magnetic microspheres (MMS) coupled to selective lectins: a new tool for large-scale extraction and purification of human pancreatic islets},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-44789},
  year      = {1989},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@article{WinotoMorbachLeyhausenMuellerRuchholtzetal.1988,
  author    = {Winoto-Morbach, S. and Leyhausen, G. and M{\"u}ller-Ruchholtz, W. and Ulrichs, Karin},
  title     = {The Electromagnetic Separation Principle: A Basis for Human Pancreatic Islet Transplantation},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-82520},
  year      = {1988},
  abstract  = {No abstract available},
  subject      = {Allergie},
  language  = {en}
}
@article{WinotoMorbachKroutHeiseretal.1994,
  author    = {Winoto-Morbach, S. and Krout, OS and Heiser, A. and Ulrichs, Karin and M{\"u}ller-Ruchholtz, W.},
  title     = {Lectin binding to acinar tissue for complete magnetophoretic purification of porcine pancreatic islets depends on the composition and pH of the incubation medium},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45183},
  year      = {1994},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@article{WillmsSchwabvonWebskyetal.2022,
  author    = {Willms, A. G. and Schwab, R. and von Websky, M. W. and Berrevoet, F. and Tartaglia, D. and S{\"o}relius, K. and Fortelny, R. H. and Bj{\"o}rck, M. and Monchal, T. and Brennfleck, F. and Bulian, D. and Beltzer, C. and Germer, C. T. and Lock, J. F.},
  title     = {Factors influencing the fascial closure rate after open abdomen treatment: Results from the European Hernia Society (EuraHS) Registry. Surgical technique matters},
  series = {Hernia},
  volume    = {26},
  journal   = {Hernia},
  number    = {1},
  organization    = {EURAHS Open Abdomen Group},
  issn      = {1265-4906},
  doi       = {10.1007/s10029-020-02336-x},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-234871},
  pages     = {61-73},
  year      = {2022},
  abstract  = {Purpose Definitive fascial closure is an essential treatment objective after open abdomen treatment and mitigates morbidity and mortality. There is a paucity of evidence on factors that promote or prevent definitive fascial closure. Methods A multi-center multivariable analysis of data from the Open Abdomen Route of the European Hernia Society included all cases between 1 May 2015 and 31 December 2019. Different treatment elements, i.e. the use of a visceral protective layer, negative-pressure wound therapy and dynamic closure techniques, as well as patient characteristics were included in the multivariable analysis. The study was registered in the International Clinical Trials Registry Platform via the German Registry for Clinical Trials (DRK00021719). Results Data were included from 630 patients from eleven surgical departments in six European countries. Indications for OAT were peritonitis (46\%), abdominal compartment syndrome (20.5\%), burst abdomen (11.3\%), abdominal trauma (9\%), and other conditions (13.2\%). The overall definitive fascial closure rate was 57.5\% in the intention-to-treat analysis and 71\% in the per-protocol analysis. The multivariable analysis showed a positive correlation of negative-pressure wound therapy (odds ratio: 2.496, p < 0.001) and dynamic closure techniques (odds ratio: 2.687, p < 0.001) with fascial closure and a negative correlation of intra-abdominal contamination (odds ratio: 0.630, p = 0.029) and the number of surgical procedures before OAT (odds ratio: 0.740, p = 0.005) with DFC. Conclusion The clinical course and prognosis of open abdomen treatment can significantly be improved by the use of treatment elements such as negative-pressure wound therapy and dynamic closure techniques, which are associated with definitive fascial closure.},
  language  = {en}
}
@article{WiegeringSchmidAndresetal.2014,
  author    = {Wiegering, Verena and Schmid, Sophie and Andres, Oliver and Wirth, Clemens and Wiegering, Armin and Meyer, Thomas and Winkler, Beate and Schlegel, Paul G. and Eyrich, Matthias},
  title     = {Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience},
  doi       = {10.1186/2052-1839-14-18},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-110476},
  year      = {2014},
  abstract  = {Background Reliable central venous access (CVC) is essential for hematology-oncology patients since frequent puncture of peripheral veins—e.g., for chemotherapy, antibiotic administration, repeated blood sampling, and monitoring—can cause unacceptable pain and psychological trauma, as well as severe side effects in cases of extravasation of chemotherapy drugs. However, CVC lines still carry major risk factors, including thrombosis, infection (e.g., entry site, tunnel, and luminal infections), and catheter dislocation, leakage, or breakage. Methods Here we performed a retrospective database analysis to determine the incidence of CVC-associated thrombosis in a single-center cohort of 448 pediatric oncologic patients, and to analyze whether any subgroup of patients was at increased risk and thus might benefit from prophylactic anticoagulation. Results Of the 448 patients, 269 consecutive patients received a CVC, and 55 of these 269 patients (20\%) also had a thrombosis. Of these 55 patients, 43 had at least one CVC-associated thrombosis (total number of CVC-associated thrombosis: n = 52). Among all patients, the median duration of CVC exposure was 464 days. Regarding exposure time, no significant difference was found between patients with and without CVC-associated thrombosis. Subclavia catheters and advanced tumor stages seem to be the main risk factors for the development of CVC-associated thrombosis, whereas pharmacologic prophylaxis did not seem to have a relevant impact on the rate of thrombosis. Conclusions We conclude that pediatric surgeons and oncologists should pay close attention to ensuring optimal and accurate CVC placement, as this appears the most effective tool to minimize CVC-associated complications.},
  language  = {en}
}
@article{WiegeringRiegelWagneretal.2017,
  author    = {Wiegering, Armin and Riegel, Johannes and Wagner, Johanna and Kunzmann, Volker and Baur, Johannes and Walles, Thorsten and Dietz, Ulrich and Loeb, Stefan and Germer, Christoph-Thomas and Steger, Ulrich and Klein, Ingo},
  title     = {The impact of pulmonary metastasectomy in patients with previously resected colorectal cancer liver metastases},
  series = {PLoS ONE},
  volume    = {12},
  journal   = {PLoS ONE},
  number    = {3},
  doi       = {10.1371/journal.pone.0173933},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-158036},
  pages     = {e0173933},
  year      = {2017},
  abstract  = {Background 40-50\% of patients with colorectal cancer (CRC) will develop liver metastases (CRLM) during the course of the disease. One third of these patients will additionally develop pulmonary metastases. Methods 137 consecutive patients with CRLM, were analyzed regarding survival data, clinical, histological data and treatment. Results were stratified according to the occurrence of pulmonary metastases and metastases resection. Results 39\% of all patients with liver resection due to CRLM developed additional lung metastases. 44\% of these patients underwent subsequent pulmonary resection. Patients undergoing pulmonary metastasectomy showed a significantly better five-year survival compared to patients not qualified for curative resection (5-year survival 71.2\% vs. 28.0\%; p = 0.001). Interestingly, the 5-year survival of these patients was even superior to all patients with CRLM, who did not develop pulmonary metastases (77.5\% vs. 63.5\%; p = 0.015). Patients, whose pulmonary metastases were not resected, were more likely to redevelop liver metastases (50.0\% vs 78.6\%; p = 0.034). However, the rate of distant metastases did not differ between both groups (54.5 vs.53.6; p = 0.945). Conclusion The occurrence of colorectal lung metastases after curative liver resection does not impact patient survival if pulmonary metastasectomy is feasible. Those patients clearly benefit from repeated resections of the liver and the lung metastases.},
  language  = {en}
}
@article{WiegeringPfannUtheetal.2013,
  author    = {Wiegering, Armin and Pfann, Christina and Uthe, Friedrich Wilhelm and Otto, Christoph and Rycak, Lukas and M{\"a}der, Uwe and Gasser, Martin and Waaga-Gasser, Anna-Maria and Eilers, Martin and Germer, Christoph-Thomas},
  title     = {CIP2A Influences Survival in Colon Cancer and Is Critical for Maintaining Myc Expression},
  series = {PLoS ONE},
  journal   = {PLoS ONE},
  doi       = {10.1371/journal.pone.0075292},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-97252},
  year      = {2013},
  abstract  = {The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncogenic factor that stabilises the c-Myc protein. CIP2A is overexpressed in several tumours, and expression levels are an independent marker for long-term outcome. To determine whether CIP2A expression is elevated in colon cancer and whether it might serve as a prognostic marker for survival, we analysed CIP2A mRNA expression by real-time PCR in 104 colon cancer samples. CIP2A mRNA was overexpressed in colon cancer samples and CIP2A expression levels correlated significantly with tumour stage. We found that CIP2A serves as an independent prognostic marker for disease-free and overall survival. Further, we investigated CIP2A-dependent effects on levels of c-Myc, Akt and on cell proliferation in three colon cancer cell lines by silencing CIP2A using small interfering (si) and short hairpin (sh) RNAs. Depletion of CIP2A substantially inhibited growth of colon cell lines and reduced c-Myc levels without affecting expression or function of the upstream regulatory kinase, Akt. Expression of CIP2A was found to be dependent on MAPK activity, linking elevated c-Myc expression to deregulated signal transduction in colon cancer.},
  language  = {en}
}
@article{WiegeringMatthesMuehlingetal.2017,
  author    = {Wiegering, Armin and Matthes, Niels and M{\"u}hling, Bettina and Koospal, Monika and Quenzer, Anne and Peter, Stephanie and Germer, Christoph-Thomas and Linnebacher, Michael and Otto, Christoph},
  title     = {Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin},
  series = {Neoplasia},
  volume    = {19},
  journal   = {Neoplasia},
  number    = {4},
  doi       = {10.1016/j.neo.2017.01.007},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-171067},
  pages     = {301-309},
  year      = {2017},
  abstract  = {Colorectal carcinoma (CRC) is the most common cancer of the gastrointestinal tract with frequently dysregulated intracellular signaling pathways, including p53 signaling. The mainstay of chemotherapy treatment of CRC is 5-fluorouracil (5FU) and oxaliplatin. The two anticancer drugs mediate their therapeutic effect via DNA damage-triggered signaling. The small molecule reactivating p53 and inducing tumor apoptosis (RITA) is described as an activator of wild-type and reactivator of mutant p53 function, resulting in elevated levels of p53 protein, cell growth arrest, and cell death. Additionally, it has been shown that RITA can induce DNA damage signaling. It is expected that the therapeutic benefits of 5FU and oxaliplatin can be increased by enhancing DNA damage signaling pathways. Therefore, we highlighted the antiproliferative response of RITA alone and in combination with 5FU or oxaliplatin in human CRC cells. A panel of long-term established CRC cell lines (n = 9) including p53 wild-type, p53 mutant, and p53 null and primary patient-derived, low-passage cell lines (n = 5) with different p53 protein status were used for this study. A substantial number of CRC cells with pronounced sensitivity to RITA (IC\(_{50}\)< 3.0 μmol/l) were identified within established (4/9) and primary patient-derived (2/5) CRC cell lines harboring wild-type or mutant p53 protein. Sensitivity to RITA appeared independent of p53 status and was associated with an increase in antiproliferative response to 5FU and oxaliplatin, a transcriptional increase of p53 targets p21 and NOXA, and a decrease in MYC mRNA. The effect of RITA as an inducer of DNA damage was shown by a strong elevation of phosphorylated histone variant H2A.X, which was restricted to RITA-sensitive cells. Our data underline the primary effect of RITA, inducing DNA damage, and demonstrate the differential antiproliferative effect of RITA to CRC cells independent of p53 protein status. We found a substantial number of RITA-sensitive CRC cells within both panels of established CRC cell lines and primary patient-derived CRC cell lines (6/14) that provide a rationale for combining RITA with 5FU or oxaliplatin to enhance the antiproliferative response to both chemotherapeutic agents.},
  language  = {en}
}
@article{WiegeringKorbThalheimeretal.2014,
  author    = {Wiegering, Armin and Korb, Doreen and Thalheimer, Andreas and K{\"a}mmerer, Ulrike and Allmanritter, Jan and Matthes, Niels and Linnebacher, Michael and Schlegel, Nicolas and Klein, Ingo and Erg{\"u}n, S{\"u}leyman and Germer, Christoph-Thomas and Otto, Christoph},
  title     = {E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts},
  doi       = {10.1016/j.neo.2014.09.008},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-111165},
  year      = {2014},
  abstract  = {Clinical prognosis of metastasized colorectal carcinoma (CRC) is still not at desired levels and novel drugs are needed. Here, we focused on the multi-tyrosine kinase inhibitor E7080 (Lenvatinib) and assessed its therapeutic efficacy against human CRC cell lines in vitro and human CRC xenografts in vivo. The effect of E7080 on cell viability was examined on 10 humanCRCcell lines and humanendothelial cells (HUVEC). The inhibitory effect of E7080 on VEGF-induced angiogenesis was studied in an ex vivo mouse aortic ring angiogenesis assay. In addition, the efficacy of E7080 against xenografts derived fromCRC cell lines and CRC patient resection specimenswithmutated KRASwas investigated in vivo. Arelatively low cytotoxic effect of E7080 on CRC cell viabilitywas observed in vitro. Endothelial cells (HUVEC)weremore susceptible to the incubation with E7080. This is in line with the observation that E7080 demonstrated an anti-angiogenic effect in a three-dimensional ex vivo mouse aortic ring angiogenesis assay. E7080 effectively disrupted CRC cell-mediated VEGF-stimulated growth of HUVEC in vitro. Daily in vivo treatment with E7080 (5 mg/kg) significantly delayed the growth of KRAS mutated CRC xenografts with decreased density of tumor-associated vessel formations and without tumor regression. This observation is in line with results that E7080 did not significantly reduce the number of Ki67-positive cells in CRC xenografts. The results suggest antiangiogenic activity of E7080 at a dosage thatwas well tolerated by nudemice. E7080 may provide therapeutic benefits in the treatment of CRC with mutated KRAS.},
  language  = {en}
}
@article{WiegeringIsbertDietzetal.2014,
  author    = {Wiegering, Armin and Isbert, Christoph and Dietz, Ulrich A. and Kunzmann, Volker and Ackermann, Sabine and Kerscher, Alexander and Maeder, Uwe and Flentje, Michael and Schlegel, Nicolas and Reibetanz, Joachim and Germer, Christoph-Thomas and Klein, Ingo},
  title     = {Multimodal therapy in treatment of rectal cancer is associated with improved survival and reduced local recurrence - a retrospective analysis over two decades},
  doi       = {10.1186/1471-2407-14-816},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-110606},
  year      = {2014},
  abstract  = {Background The management of rectal cancer (RC) has substantially changed over the last decades with the implementation of neoadjuvant chemoradiotherapy, adjuvant therapy and improved surgery such as total mesorectal excision (TME). It remains unclear in which way these approaches overall influenced the rate of local recurrence and overall survival. Methods Clinical, histological and survival data of 658 out of 662 consecutive patients with RC were analyzed for treatment and prognostic factors from a prospectively expanded single-institutional database. Findings were then stratified according to time of diagnosis in patient groups treated between 1993 and 2001 and 2002 and 2010. Results The study population included 658 consecutive patients with rectal cancer between 1993 and 2010. Follow up data was available for 99.6\% of all 662 treated patients. During the time period between 2002 and 2010 significantly more patients underwent neoadjuvant chemoradiotherapy (17.6\% vs. 60\%) and adjuvant chemotherapy (37.9\% vs. 58.4\%). Also, the rate of reported TME during surgery increased. The rate of local or distant metastasis decreased over time, and tumor related 5-year survival increased significantly with from 60\% to 79\%. Conclusion In our study population, the implementation of treatment changes over the last decade improved the patient's outcome significantly. Improvements were most evident for UICC stage III rectal cancer.},
  language  = {en}
}
@article{WidderKelmReibetanzetal.2022,
  author    = {Widder, Anna and Kelm, Matthias and Reibetanz, Joachim and Wiegering, Armin and Matthes, Niels and Germer, Christoph-Thomas and Seyfried, Florian and Flemming, Sven},
  title     = {Robotic-assisted versus laparoscopic left hemicolectomy — postoperative inflammation status, short-term outcome and cost effectiveness},
  series = {International Journal of Environmental Research and Public Health},
  volume    = {19},
  journal   = {International Journal of Environmental Research and Public Health},
  number    = {17},
  issn      = {1660-4601},
  doi       = {10.3390/ijerph191710606},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-286203},
  year      = {2022},
  abstract  = {Robotic-assisted colon surgery may contain advantages over the laparoscopic approach, but clear evidence is sparse. This study aimed to analyze postoperative inflammation status, short-term outcome and cost-effectiveness of robotic-assisted versus laparoscopic left hemicolectomy. All consecutive patients who received minimal-invasive left hemicolectomy at the Department of Surgery I at the University Hospital of Wuerzburg in 2021 were prospectively included. Importantly, no patient selection for either procedure was carried out. The robotic-assisted versus laparoscopic approaches were compared head to head for postoperative short-term outcomes as well as cost-effectiveness. A total of 61 patients were included, with 26 patients having received a robotic-assisted approach. Baseline characteristics did not differ among the groups. Patients receiving a robotic-assisted approach had a significantly decreased length of hospital stay as well as lower rates of complications in comparison to patients who received laparoscopic surgery (n = 35). In addition, C-reactive protein as a marker of systemic stress response was significantly reduced postoperatively in patients who were operated on in a robotic-assisted manner. Consequently, robotic-assisted surgery could be performed in a cost-effective manner. Thus, robotic-assisted left hemicolectomy represents a safe and cost-effective procedure and might improve patient outcomes in comparison to laparoscopic surgery.},
  language  = {en}
}
@article{WidderBackhausWierlemannetal.,
  author    = {Widder, A. and Backhaus, J. and Wierlemann, A. and Hering, I. and Flemming, S. and Hankir, M. and Germer, C.-T. and Wiegering, A. and Lock, J. F. and K{\"o}nig, S. and Seyfried, F.},
  title     = {Optimizing laparoscopic training efficacy by 'deconstruction into key steps': a randomized controlled trial with novice medical students},
  series = {Surgical Endoscopy},
  volume    = {36},
  journal   = {Surgical Endoscopy},
  number    = {12},
  doi       = {10.1007/s00464-022-09408-2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-323969},
  pages     = {8726-8736},
  abstract  = {Background Simulator training is an effective way of acquiring laparoscopic skills but there remains a need to optimize teaching methods to accelerate learning. We evaluated the effect of the mental exercise 'deconstruction into key steps' (DIKS) on the time required to acquire laparoscopic skills. Methods A randomized controlled trial with undergraduate medical students was implemented into a structured curricular laparoscopic training course. The intervention group (IG) was trained using the DIKS approach, while the control group (CG) underwent the standard course. Laparoscopic performance of all participants was video-recorded at baseline (t0), after the first session (t1) and after the second session (t2) nine days later. Two double-blinded raters assessed the videos. The Impact of potential covariates on performance (gender, age, prior laparoscopic experience, self-assessed motivation and self-assessed dexterity) was evaluated with a self-report questionnaire. Results Both the IG (n = 58) and the CG (n = 68) improved their performance after each training session (p < 0.001) but with notable differences between sessions. Whereas the CG significantly improved their performance from t0 -t1 (p < 0.05), DIKS shortened practical exercise time by 58\% so that the IG outperformed the CG from t1 -t2, (p < 0.05). High self-assessed motivation and dexterity associated with significantly better performance (p < 0.05). Male participants demonstrated significantly higher overall performance (p < 0.05). Conclusion Mental exercises like DIKS can improve laparoscopic performance and shorten practice times. Given the limited exposure of surgical residents to simulator training, implementation of mental exercises like DIKS is highly recommended. Gender, self-assessed dexterity, and motivation all appreciably influence performance in laparoscopic training.},
  language  = {en}
}
@article{WedelHudakSeibeletal.2011,
  author    = {Wedel, Steffen and Hudak, Lukasz and Seibel, Jens-Michael and Makarevic, Jasmina and Juengel, Eva and Tsaur, Igor and Waaga-Gasser, Ana and Haferkamp, Axel and Blaheta, Roman A.},
  title     = {Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis},
  series = {BMC Cancer},
  volume    = {11},
  journal   = {BMC Cancer},
  number    = {375},
  doi       = {10.1186/1471-2407-11-375},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-141075},
  pages     = {1-14},
  year      = {2011},
  abstract  = {Background: Single drug use has not achieved satisfactory results in the treatment of prostate cancer, despite application of increasingly widespread targeted therapeutics. In the present study, the combined impact of the mammalian target of rapamycin (mTOR)-inhibitor RAD001, the dual EGFr and VGEFr tyrosine kinase inhibitor AEE788 and the histone deacetylase (HDAC)-inhibitor valproic acid (VPA) on prostate cancer growth and adhesion in vitro was investigated. Methods: PC-3, DU-145 and LNCaP cells were treated with RAD001, AEE788 or VPA or with a RAD-AEE-VPA combination. Tumor cell growth, cell cycle progression and cell cycle regulating proteins were then investigated by MTT-assay, flow cytometry and western blotting, respectively. Furthermore, tumor cell adhesion to vascular endothelium or to immobilized extracellular matrix proteins as well as migratory properties of the cells was evaluated, and integrin alpha and beta subtypes were analyzed. Finally, effects of drug treatment on cell signaling pathways were determined. Results: All drugs, separately applied, reduced tumor cell adhesion, migration and growth. A much stronger anticancer effect was evoked by the triple drug combination. Particularly, cdk1, 2 and 4 and cyclin B were reduced, whereas p27 was elevated. In addition, simultaneous application of RAD001, AEE788 and VPA altered the membranous, cytoplasmic and gene expression pattern of various integrin alpha and beta subtypes, reduced integrin-linked kinase (ILK) and deactivated focal adhesion kinase (FAK). Signaling analysis revealed that EGFr and the downstream target Akt, as well as p70S6k was distinctly modified in the presence of the drug combination. Conclusions: Simultaneous targeting of several key proteins in prostate cancer cells provides an advantage over targeting a single pathway. Since strong anti-tumor properties became evident with respect to cell growth and adhesion dynamics, the triple drug combination might provide progress in the treatment of advanced prostate cancer.},
  language  = {en}
}
@article{WeberGlutschGeissingeretal.2020,
  author    = {Weber, J. and Glutsch, V. and Geissinger, E. and Haug, L. and Lock, J.F. and Schneider, F. and Kneitz, H. and Goebeler, M. and Schilling, B. and Gesierich, A.},
  title     = {Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease},
  series = {British Journal of Dermatology},
  volume    = {183},
  journal   = {British Journal of Dermatology},
  number    = {3},
  doi       = {10.1111/bjd.18739},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-213520},
  pages     = {559-563},
  year      = {2020},
  abstract  = {The introduction of new therapeutic agents has revolutionized the treatment of metastatic melanoma. The approval of adjuvant anti-programmed death-1 monotherapy with nivolumab or pembrolizumab, and dabrafenib plus trametinib has recently set a new landmark in the treatment of stage III melanoma. Now, clinical trials have shown that immune checkpoint blockade can be performed in a neoadjuvant setting, an approach established as a standard therapeutic approach for other tumour entities such as breast cancer. Recent studies suggest that a pathological response achieved by neoadjuvant immunotherapy is associated with long-term tumour control and that short neoadjuvant application of checkpoint inhibitors may be superior to adjuvant therapy. Most recently, neoadjuvant ipilimumab plus nivolumab in stage III melanoma was reported. With two courses of dose-optimized ipilimumab (1 mg kg-1) combined with nivolumab (3 mg kg-1), pathological responses were observed in 77\% of patients, while only 20\% of patients experienced grade 3 or 4 adverse events. However, the neoadjuvant trials employing combined immune checkpoint blockade conducted so far have excluded patients with in transit metastases, a common finding in stage III melanoma. Here we report four patients with in transit metastases or an advanced primary tumour who have been treated with neoadjuvant ipilimumab plus nivolumab according to the OpACIN-neo trial scheme (arm B). All patients achieved radiological disease control and a pathological response. None of the patients has relapsed so far.},
  language  = {en}
}
@inproceedings{WangUlrichsMuellerRuchholtz1993,
  author    = {Wang, HY and Ulrichs, Karin and M{\"u}ller-Ruchholtz, W.},
  title     = {Down-Regulation of Xenophile Antibodies by Specific Immunosuppressive Protocols to Facilitate Xenogeneic Organ Transplantation},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45669},
  year      = {1993},
  abstract  = {No abstract available},
  subject      = {Immunbiologie},
  language  = {en}
}
@article{WallstabeBussemerGroeberBeckeretal.2020,
  author    = {Wallstabe, Julia and Bussemer, Lydia and Groeber-Becker, Florian and Freund, Lukas and Alb, Mirian and Dragan, Mariola and Waaga-Gasser, Ana Maria and Jakubietz, Rafael and Kneitz, Hermann and Rosenwald, Andreas and Rebhan, Silke and Walles, Heike and Mielke, Stephan},
  title     = {Inflammation-Induced Tissue Damage Mimicking GvHD in Human Skin Models as Test Platform for Immunotherapeutics},
  series = {ALTEX},
  volume    = {37},
  journal   = {ALTEX},
  number    = {3},
  doi       = {10.14573/altex.1907181},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-229974},
  pages     = {429-440},
  year      = {2020},
  abstract  = {Due to the rapidly increasing development and use of cellular products, there is a rising demand for non-animal-based test platforms to predict, study and treat undesired immunity. Here, we generated human organotypic skin models from human biopsies by isolating and expanding keratinocytes, fibroblasts and microvascular endothelial cells and seeding these components on a collagen matrix or a biological vascularized scaffold matrix in a bioreactor. We then were able to induce inflammation-mediated tissue damage by adding pre-stimulated, mismatched allogeneic lymphocytes and/or inflammatory cytokine-containing supernatants histomorphologically mimicking severe graft versus host disease (GvHD) of the skin. This could be prevented by the addition of immunosuppressants to the models. Consequently, these models harbor a promising potential to serve as a test platform for the prediction, prevention and treatment of GvHD. They also allow functional studies of immune effectors and suppressors including but not limited to allodepleted lymphocytes, gamma-delta T cells, regulatory T cells and mesenchymal stromal cells, which would otherwise be limited to animal models. Thus, the current test platform, developed with the limitation that no professional antigen presenting cells are in place, could greatly reduce animal testing for investigation of novel immune therapies.},
  language  = {en}
}
@article{WallaschekReuterSilkenatetal.2021,
  author    = {Wallaschek, Nina and Reuter, Saskia and Silkenat, Sabrina and Wolf, Katharina and Niklas, Carolin and {\"O}zge, Kayisoglu and Aguilar, Carmen and Wiegering, Armin and Germer, Christoph-Thomas and Kircher, Stefan and Rosenwald, Andreas and Shannon-Lowe, Claire and Bartfeld, Sina},
  title     = {Ephrin receptor A2, the epithelial receptor for Epstein-Barr virus entry, is not available for efficient infection in human gastric organoids},
  series = {PLoS Pathogens},
  volume    = {17},
  journal   = {PLoS Pathogens},
  number    = {2},
  doi       = {10.1371/journal.ppat.1009210},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-259206},
  pages     = {e1009210},
  year      = {2021},
  abstract  = {Epstein-Barr virus (EBV) is best known for infection of B cells, in which it usually establishes an asymptomatic lifelong infection, but is also associated with the development of multiple B cell lymphomas. EBV also infects epithelial cells and is associated with all cases of undifferentiated nasopharyngeal carcinoma (NPC). EBV is etiologically linked with at least 8\% of gastric cancer (EBVaGC) that comprises a genetically and epigenetically distinct subset of GC. Although we have a very good understanding of B cell entry and lymphomagenesis, the sequence of events leading to EBVaGC remains poorly understood. Recently, ephrin receptor A2 (EPHA2) was proposed as the epithelial cell receptor on human cancer cell lines. Although we confirm some of these results, we demonstrate that EBV does not infect healthy adult stem cell-derived gastric organoids. In matched pairs of normal and cancer-derived organoids from the same patient, EBV only reproducibly infected the cancer organoids. While there was no clear pattern of differential expression between normal and cancer organoids for EPHA2 at the RNA and protein level, the subcellular location of the protein differed markedly. Confocal microscopy showed EPHA2 localization at the cell-cell junctions in primary cells, but not in cancer cell lines. Furthermore, histologic analysis of patient tissue revealed the absence of EBV in healthy epithelium and presence of EBV in epithelial cells from inflamed tissue. These data suggest that the EPHA2 receptor is not accessible to EBV on healthy gastric epithelial cells with intact cell-cell contacts, but either this or another, yet to be identified receptor may become accessible following cellular changes induced by inflammation or transformation, rendering changes in the cellular architecture an essential prerequisite to EBV infection.},
  language  = {en}
}
@article{WagnerEikenHaubitzetal.2019,
  author    = {Wagner, Johanna and Eiken, Barbara and Haubitz, Imme and Lichthardt, Sven and Matthes, Niels and L{\"o}b, Stefan and Klein, Ingo and Germer, Christoph-Thomas and Wiegering, Armin},
  title     = {Suprapubic bladder drainage and epidural catheters following abdominal surgery—a risk for urinary tract infections?},
  series = {PLoS ONE},
  volume    = {14},
  journal   = {PLoS ONE},
  number    = {1},
  doi       = {10.1371/journal.pone.0209825},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-177731},
  pages     = {e0209825},
  year      = {2019},
  abstract  = {Background Epidural catheters are state of the art for postoperative analgesic in abdominal surgery. Due to neurolysis it can lead to postoperative urinary tract retention (POUR), which leads to prolonged bladder catheterization, which has an increased risk for urinary tract infections (UTI). Our aim was to identify the current perioperative management of urinary catheters and, second, to identify the optimal time of suprapubic bladder catheter removal in regard to the removal of the epidural catheter. Methods We sent a questionnaire to 102 German hospitals and analyzed the 83 received answers to evaluate the current handling of bladder drainage and epidural catheters. Then, we conducted a retrospective study including 501 patients, who received an epidural and suprapubic catheter after abdominal surgery at the University Hospital W{\"u}rzburg. We divided the patients into three groups according to the point in time of suprapubic bladder drainage removal in regard to the removal of the epidural catheter and analyzed the onset of a UTI. Results Our survey showed that in almost all hospitals (98.8\%), patients received an epidural catheter and a bladder drainage after abdominal surgery. The point in time of urinary catheter removal was equally distributed between before, simultaneously and after the removal of the epidural catheter (respectively: ~28-29\%). The retrospective study showed a catheter-associated UTI in 6.7\%. Women were affected significantly more often than men (10,7\% versus 2,5\%, p<0.001). There was a non-significant trend to more UTIs when the suprapubic catheter was removed after the epidural catheter (before: 5.7\%, after: 8.4\%). Conclusion The point in time of suprapubic bladder drainage removal in relation to the removal of the epidural catheter does not seem to correlate with the rate of UTIs. The current handling in Germany is inhomogeneous, so further studies to standardize treatment are recommended.},
  language  = {en}
}
@article{WagnerWetzWiegeringetal.2021,
  author    = {Wagner, Johanna C. and Wetz, Anja and Wiegering, Armin and Lock, Johan F. and L{\"o}b, Stefan and Germer, Christoph-Thomas and Klein, Ingo},
  title     = {Successful surgical closure of infected abdominal wounds following preconditioning with negative pressure wound therapy},
  series = {Langenbeck's Archives of Surgery},
  volume    = {406},
  journal   = {Langenbeck's Archives of Surgery},
  number    = {7},
  issn      = {1435-2451},
  doi       = {10.1007/s00423-021-02221-w},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-267541},
  pages     = {2479-2487},
  year      = {2021},
  abstract  = {Purpose Traditionally, previous wound infection was considered a contraindication to secondary skin closure; however, several case reports describe successful secondary wound closure of wounds "preconditioned" with negative pressure wound therapy (NPWT). Although this has been increasingly applied in daily practice, a systematic analysis of its feasibility has not been published thus far. The aim of this study was to evaluate secondary skin closure in previously infected abdominal wounds following treatment with NPWT. Methods Single-center retrospective analysis of patients with infected abdominal wounds treated with NPWT followed by either secondary skin closure referenced to a group receiving open wound therapy. Endpoints were wound closure rate, wound complications (such as recurrent infection or hernia), and perioperative data (such as duration of NPWT or hospitalization parameters). Results One hundred ninety-eight patients during 2013-2016 received a secondary skin closure after NPWT and were analyzed and referenced to 67 patients in the same period with open wound treatment after NPWT. No significant difference in BMI, chronic immunosuppressive medication, or tobacco use was found between both groups. The mean duration of hospital stay was 30 days with a comparable duration in both patient groups (29 versus 33 days, p = 0.35). Interestingly, only 7.7\% of patients after secondary skin closure developed recurrent surgical site infection and in over 80\% of patients were discharged with closed wounds requiring only minimal outpatient wound care. Conclusion Surgical skin closure following NPWT of infected abdominal wounds is a good and safe alternative to open wound treatment. It prevents lengthy outpatient wound therapy and is expected to result in a higher quality of life for patients and reduce health care costs.},
  language  = {en}
}
@article{WaagaUlrichsKrzymanskietal.1990,
  author    = {Waaga, AM and Ulrichs, Karin and Krzymanski, M. and Treumer, J. and Hansmann, ML and Rommel, T. and M{\"u}ller-Ruchholz, W.},
  title     = {The immunosuppressive agent 15-deoxyspergualin induces tolerance and modulates MHC-antigen expression and interleukin-1 production in the early phase of rat allograft responses},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45253},
  year      = {1990},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@article{WaagaKrzymanskiUlrichsetal.1993,
  author    = {Waaga, AM and Krzymanski, M. and Ulrichs, Karin and Wierusz-Wysocka, Bogna and M{\"u}ller-Buchholtz, Wolfgang},
  title     = {Hematological effects of the new immunosuppressive drug 15-deoxyspergualin},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-44701},
  year      = {1993},
  abstract  = {Since systematic hematological studies on blood and bone marrow changes after treatment with 15-Deoxyspergualin (DOS) are lacking, a quantitative assessment was performed fourteen or twenty eight days after intraperitoneal application of DOS to rats. Further observations done 7 and 14 days after discontinuation of DOS administration allowed analysis of banc marrow regeneration. DOS induced lymphocytopenia, granUlocytopenia and anemia with a decrease of bone marrow cellularity due to suppression of cell maturation. The effect was dose-dependent and bone marrow as well as blood changes were observed in animals treated with doses from 0.5 to 10.0 mg/kg DOS. Within 14 days after termination of the treatment, rapid recovery with normalization of all hematological parameters was observed. In the light of our data, these hematological side effects may not be a major disadvantage, if DOS is used in doses below 2.5 mg/kg, and for a course of therapy which is limited to 7 to 14 days.},
  subject      = {Chirurgie},
  language  = {en}
}
@article{vonRahdenKircherLazariotouetal.2011,
  author    = {von Rahden, Burkhard H.A. and Kircher, Stefan and Lazariotou, Maria and Reiber, Christoph and Stuermer, Luisa and Otto, Christoph and Germer, Christoph T. and Grimm, Martin},
  title     = {LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's Esophagus?},
  series = {Journal of Experimental \& Clinical Cancer Research},
  volume    = {30},
  journal   = {Journal of Experimental \& Clinical Cancer Research},
  number    = {23},
  doi       = {10.1186/1756-9966-30-23},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-137783},
  year      = {2011},
  abstract  = {Background Investigation of the expression of an intestinal stem cell marker in esophageal adenocarcinomas (EAC) with and without Barrett's Esophagus (BE), with respect to a cancer stem cell (CSC) hypothesis. Materials and methods Expression of a putative intestinal stem cell marker LgR5 was analyzed in esophageal cancer specimen (n = 70: 41 EAC with BE, 19 EAC without BE, and n = 10 esophageal squamous-cell carcinomas, ESCC) and in the adenocarcinoma cell line OE-33. Ki-67 and Cdx-2 were co-labelled with LgR5 in double staining experiments. Immunhistochemical expression results were confirmed by RT-PCR and correlated with tumor stage and five-year survival rates. Results LgR5was found expressed in 35 of 41 (85\%) EAC with BE and in 16 of 19 (81\%) EAC without BE. By contrast, LgR5 was not found to be expressed in ESCC. Quantification of immunolabeling showed 15\% LgR5+ cells in EAC with BE, 32\% LgR5+ cells in adjacent BE and 13\% in EAC without BE. Immunofluorescence double staining experiments with LgR5 and Ki-67 revealed a subpopulation (~5\%) of proliferating LgR+/Ki-67+ cells. On mRNA-level, expression of LgR5 was higher in BE in comparison to EAC (p = 0.0159). High levels of LgR5 expression in BE associated EAC were associated with poorer survival in univariate analysis. Conclusion The stem cell marker LgR5 is expressed in EAC, irrespective of association with BE, and appears to have negative impact on survival. The subset of proliferating LgR5+ cells (<5\%) might resemble rapidly cycling CSCs, which needs to be substantiated in further investigations.},
  language  = {en}
}
@article{vonRahdenKircherLazariotouetal.2011,
  author    = {von Rahden, Burkhard H. A. and Kircher, Stefan and Lazariotou, Maria and Reiber, Christoph and Stuermer, Luisa and Otto, Christoph and Germer, Christoph T. and Grimm, Martin},
  title     = {LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's Esophagus?},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68810},
  year      = {2011},
  abstract  = {Background: Investigation of the expression of an intestinal stem cell marker in esophageal adenocarcinomas (EAC) with and without Barrett's Esophagus (BE), with respect to a cancer stem cell (CSC) hypothesis. Materials and methods: Expression of a putative intestinal stem cell marker LgR5 was analyzed in esophageal cancer specimen (n = 70: 41 EAC with BE, 19 EAC without BE, and n = 10 esophageal squamous-cell carcinomas, ESCC) and in the adenocarcinoma cell line OE-33. Ki-67 and Cdx-2 were co-labelled with LgR5 in double staining experiments. Immunhistochemical expression results were confirmed by RT-PCR and correlated with tumor stage and five-year survival rates. Results: LgR5was found expressed in 35 of 41 (85\%) EAC with BE and in 16 of 19 (81\%) EAC without BE. By contrast, LgR5 was not found to be expressed in ESCC. Quantification of immunolabeling showed 15\% LgR5+ cells in EAC with BE, 32\% LgR5+ cells in adjacent BE and 13\% in EAC without BE. Immunofluorescence double staining experiments with LgR5 and Ki-67 revealed a subpopulation (~5\%) of proliferating LgR+/Ki-67+ cells. On mRNAlevel, expression of LgR5 was higher in BE in comparison to EAC (p = 0.0159). High levels of LgR5 expression in BE associated EAC were associated with poorer survival in univariate analysis. Conclusion: The stem cell marker LgR5 is expressed in EAC, irrespective of association with BE, and appears to have negative impact on survival. The subset of proliferating LgR5+ cells (<5\%) might resemble rapidly cycling CSCs, which needs to be substantiated in further investigations.},
  subject      = {Medizin},
  language  = {en}
}
@article{VonGaudeckerUlrichsMuellerRuchholtz1989,
  author    = {Von Gaudecker, Brita and Ulrichs, Karin and M{\"u}ller-Ruchholtz, Wolfgang},
  title     = {Immunoelectron microscopic localization of MHC structures in isolated pancreatic rat islets},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45596},
  year      = {1989},
  abstract  = {An immunogold-silver enhancement technique, which combines effective labeling of viable isolated islets with the ultrastructural resolution of cytological details, was applied in electron microscopy to identify major histocompatibility complex (MHC) structures on islet cells. Incubation of freshly isolated islets from CAP (RT1C) and LEW (RT1') rats with OX18, an MHC class I antibody, showed strong positive reactivity in macrophages and/or dendritic-like cells (M0-DCs) and vascular endothelial cells (VEs) and a comparatively weaker reactivity in endocrine a-, p-, and 8-ce"s. With MHC class" antibody OX6 (anti-I-A), M0-DCs were strongly labeled in both rat strains on the surface and on internal structures. Three of five particularly high titered batches of OX6 revealed MHC class" expression on VE and p-ce"s. Four days of in vitro culture in combination with a high concentration of glucose and interferon-'Y induced strong enhancement of MHC class I structures and, to a lesser extent, class " structures on p-ce"s.},
  subject      = {Immunbiologie},
  language  = {en}
}
@article{UttingerRiedmeierReibetanzetal.2022,
  author    = {Uttinger, Konstantin L. and Riedmeier, Maria and Reibetanz, Joachim and Meyer, Thomas and Germer, Christoph Thomas and Fassnacht, Martin and Wiegering, Armin and Wiegering, Verena},
  title     = {Adrenalectomies in children and adolescents in Germany - a diagnose related groups based analysis from 2009-2017},
  series = {Frontiers in Endocrinology},
  volume    = {13},
  journal   = {Frontiers in Endocrinology},
  issn      = {1664-2392},
  doi       = {10.3389/fendo.2022.914449},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-282280},
  year      = {2022},
  abstract  = {Background Adrenalectomies are rare procedures especially in childhood. So far, no large cohort study on this topic has been published with data on to age distribution, operative procedures, hospital volume and operative outcome. Methods This is a retrospective analysis of anonymized nationwide hospital billing data (DRG data, 2009-2017). All adrenal surgeries (defined by OPS codes) of patients between the age 0 and 21 years in Germany were included. Results A total of 523 patient records were identified. The mean age was 8.6 ± 7.7 years and 262 patients were female (50.1\%). The majority of patients were between 0 and 5 years old (52\% overall), while 11.1\% were between 6 and 11 and 38.8\% older than 12 years. The most common diagnoses were malignant neoplasms of the adrenal gland (56\%, mostly neuroblastoma) with the majority being younger than 5 years. Benign neoplasms in the adrenal gland (D350) account for 29\% of all cases with the majority of affected patients being 12 years or older. 15\% were not defined regarding tumor behavior. Overall complication rate was 27\% with a clear higher complication rate in resection for malignant neoplasia of the adrenal gland. Bleeding occurrence and transfusions are the main complications, followed by the necessary of relaparotomy. There was an uneven patient distribution between hospital tertiles (low volume, medium and high volume tertile). While 164 patients received surgery in 85 different "low volume" hospitals (0.2 cases per hospital per year), 205 patients received surgery in 8 different "high volume" hospitals (2.8 cases per hospital per year; p<0.001). Patients in high volume centers were significant younger, had more extended resections and more often malignant neoplasia. In multivariable analysis younger age, extended resections and open procedures were independent predictors for occurrence of postoperative complications. Conclusion Overall complication rate of adrenalectomies in the pediatric population in Germany is low, demonstrating good therapeutic quality. Our analysis revealed a very uneven distribution of patient volume among hospitals.},
  language  = {en}
}
@article{UlrichsYuDunckeretal.1984,
  author    = {Ulrichs, Karin and Yu, MY and Duncker, D. and M{\"u}ller-Ruchholtz, W.},
  title     = {Immunosuppression by cytostatic drugs?},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45574},
  year      = {1984},
  abstract  = {In the present study, an attempt was made to characterize the immunomodulating abilities of the cytostatic drugs cydophosphamide, ifosfamide, vinblastine, vincristine, procarbazine, dacarbazine, 6-mercaptopurine, methotrexate, 5-f/uor-uracil and adriamycine in a defined experimental model. Varying combinations of drug plus transplantation alloantigen, (C3H-lymphocytes) were injected into Balb/c mice at different time intervals in vivo. The resulting T-effector cell reactivity was determined in vitro with the microcytotoxicity assay on day + 5 for primary (r) and day + 7 for secondary (2°) sensitized mice. According to the type of drug (alkylating agent vs. vinca alkaloid vs. antimetabolite vs. cytostatic antibiotic), the dosage (20\% LD50 vs. 60\% LD50), the state of sensitization (r vs. 2° sensitized recipients), and the time of drug application in relation to the antigen treatment on day 0 (in varying steps from day -6 to day +4), so-called "pharmaconantigen- variation-effects" (PA VE) were established for each of the investigated drugs in form of reaction profiles. The results were as folIows: (1) For almost alt substances, characteristic reaction profiles involving immunostimulation and/or immunosuppression could be established. Similarities in the profiles of different substances made it possible to classify the drugs according to different reaction types. The reaction type however is not definitely correlated to the biochemical mechanism of drug action. (2) The PA VE are decisively inf/uenced by so me of the biological parameters, such as the time of drug application in relation to the antigen treatment and the state of sensitization but relatively !ittle by the dosage of the drug. (3) Considering the different processes occurring du ring primary and secondary immune responses, the PAVE may give hints for a distinct manipulation of the immunoregulation and thus information on the immunobiological mechanism of drug action.},
  subject      = {Immunologie},
  language  = {en}
}
@article{UlrichsWinotoMorbachHeringetal.1990,
  author    = {Ulrichs, Karin and Winoto-Morbach, S. and Hering, B. and M{\"u}ller-Ruchholtz, W.},
  title     = {A Useful Biotechnological Approach to Solve the Problem of Graft Purity in Human Pancreatic Islet Transplantation},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45619},
  year      = {1990},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@article{UlrichsWangMuellerBuchholtz1994,
  author    = {Ulrichs, Karin and Wang, H. and M{\"u}ller-Buchholtz, W.},
  title     = {Down-regulation of xenophile antibodies by 15-deoxyspergualin in an experimental animal model},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-44733},
  year      = {1994},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@article{UlrichsSchangKelleretal.1984,
  author    = {Ulrichs, Karin and Schang, T. and Keller, R. and M{\"u}ller-Ruchholtz, W.},
  title     = {Reactivity of pancreas islet cells with antisera of known specificity},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45466},
  year      = {1984},
  abstract  = {No abstract available},
  language  = {en}
}
@article{UlrichsNoethlingKelleretal.1987,
  author    = {Ulrichs, Karin and N{\"o}thling, R. and Keller, R. and Heusermann, U. and M{\"u}ller-Buchholtz, W.},
  title     = {Genetically determined variation of constitutive major histocompatibility complex class II antigen expression in various rat strains and cell types},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-44769},
  year      = {1987},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@article{UlrichsMuellerRuchholtz1991,
  author    = {Ulrichs, Karin and M{\"u}ller-Ruchholtz, Wolfgang},
  title     = {Modulation of pancreatic islet allo immunogenicity and immunobiological in vitro and in vivo consequences},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-78261},
  year      = {1991},
  abstract  = {No abstract available.},
  subject      = {Immunobiologie},
  language  = {en}
}
@misc{UlrichsMuellerRuchholtz1989,
  author    = {Ulrichs, Karin and M{\"u}ller-Ruchholtz, W.},
  title     = {Identification and Manipulation of Human Islet Alloimmunogenicity: Morphologic and Functional in Vitro Studies with Various Islet Preparations},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45584},
  year      = {1989},
  abstract  = {No abstract available},
  subject      = {Immunbiologie},
  language  = {en}
}
@article{UlrichsMuellerRuchholtz1988,
  author    = {Ulrichs, Karin and M{\"u}ller-Ruchholtz, W.},
  title     = {Expression of MHC Structures on Immunologically Reactive and Non Reactive Cells in Islets of Langerhans and Other Tissues},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45557},
  year      = {1988},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@article{UlrichsMuellerRuchholtz1985,
  author    = {Ulrichs, Karin and M{\"u}ller-Ruchholtz, W.},
  title     = {Further Analyses of Pancreas Islet Immunogenicity, a Major Barrier to Successful Islet Transplantation},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45563},
  year      = {1985},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@article{UlrichsMuellerRuchholtz1989,
  author    = {Ulrichs, Karin and M{\"u}ller-Ruchholtz, W.},
  title     = {Significant manipulative procedures to reduce immunogenicity of human islet allografts},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45155},
  year      = {1989},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@article{UlrichsMuellerRuchholtz1990,
  author    = {Ulrichs, Karin and M{\"u}ller-Ruchholtz, W.},
  title     = {Mixed lymphocyte islet culture (MLIC) and its use in manipulation of human islet alloimmunogenicity},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45515},
  year      = {1990},
  abstract  = {No abstract available},
  language  = {en}
}
@article{UlrichsMuellerBuchholtz1985,
  author    = {Ulrichs, Karin and M{\"u}ller-Buchholtz, W.},
  title     = {MHC class II antigen expression on the various cells of normal and activated isolated pancreatic islets},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-44722},
  year      = {1985},
  abstract  = {It is the aim of this study to characterize and quantify the cells within isolated rat islets that express MHC class 11 antigens. A set of five monoelonal antibodies and two polyclonal antisera of defined specificlty were used in combination with a newly devised procedure for three·dimensional immunofluorescence evaluation of intact islets. It is shown that in addition to passen· ger cells, such as Iymphocytes, macro· phages, and dendrlticlike cells, vascular endothelial and endocrine cells are also capable of expressing class 11 antigens. This expression Is strongly influenced by in vitro culture. pregnancy, streptozotocin- induced diabetes, transplantation trauma, and alloantigenic stimuli. The pos· sible role of the above cells in antigen presentation related to islet transplantation is discussed.},
  language  = {en}
}
@article{UlrichsKuhlencordtMuellerRuchholtz1979,
  author    = {Ulrichs, Karin and Kuhlencordt, KM and M{\"u}ller-Ruchholtz, W.},
  title     = {Plating inhibition assay (PIA): a new test for cell mediated cytotoxicity},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45443},
  year      = {1979},
  abstract  = {No abstract available},
  language  = {en}
}
@article{UlrichsKellerMuellerRuchholtz1985,
  author    = {Ulrichs, Karin and Keller, R. and M{\"u}ller-Ruchholtz, W.},
  title     = {Serological demonstration and manipulation of passenger cells (PC) in pancreas islet grafts},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-72944},
  year      = {1985},
  abstract  = {No abstract available},
  subject      = {Immunobiologie},
  language  = {en}
}
@article{UlrichsKaitschickBartlettetal.1992,
  author    = {Ulrichs, Karin and Kaitschick, J. and Bartlett, R. and M{\"u}ller-Ruchholtz, W.},
  title     = {Suppression of natural xenophile antibodies with the novel immunomodulating drug leflunomide},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45202},
  year      = {1992},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@article{UlrichsEulerSchroederetal.1992,
  author    = {Ulrichs, Karin and Euler, HH and Schroeder, JO and M{\"u}ller-Ruchhholtz, W.},
  title     = {Long-term specific suppression of antibody production by plasmapheresis and a short-term course of cyclophosphamide},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45198},
  year      = {1992},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}
@inproceedings{UlrichsEulerMuellerRuchholtz1991,
  author    = {Ulrichs, Karin and Euler, HH and M{\"u}ller-Ruchholtz, W.},
  title     = {A Clinically Successful Protocol to Suppress Autoantibody Production in SLE Patients Is Analyzed For Its Efficacy To Inhibit Natural Xenophile Antibodies (NXA)},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45693},
  year      = {1991},
  abstract  = {No abstract available},
  language  = {en}
}
@article{UlrichsEcksteinMuellerBuchholtz1994,
  author    = {Ulrichs, Karin and Eckstein, V. and M{\"u}ller-Buchholtz, W.},
  title     = {Xenogeneic T-cell-mediated immune reactivity in the model of pig-to-humans: first findings with native stimulator cells},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-44755},
  year      = {1994},
  abstract  = {No abstract available},
  subject      = {Chirurgie},
  language  = {en}
}